Clinical Center News
Fall 2019

Clinical trial with alpha particle radiation treatment attempts to target and destroy cancer cells

Patient standing with care providers
On July 23, Keith Grant (second from right), from Maryland, was the first patient in the United States to receive radioisotope Thorium-227 in treatment for mesothelioma. Grant will return every six weeks to the NIH Clinical Center for therapy. Grant stands with his care team, Maria Agra, a research nurse for Frederick National Laboratory, Dr. Frank Lin, chief of the Targeted Radionuclide Therapy Section at NCI, and Dr. Raffit Hassan, chief of the Thoracic and GI Malignancies Branch and head or the Thoracic Oncology Section at NCI.

On July 23, researchers in the NIH Clinical Center treated the first patient in the U.S. with radioisotope Thorium-227 for mesothelioma. The clinical trial uses Thorium-227 to target and attack a protein called mesothelin, which is highly expressed in many cancers.

Thorium-227 is an unstable radio-isotope that emits an alpha particle upon undergoing radioactive decay, explained Dr. Frank Lin, Chief of the Targeted Radionuclide Therapy Section at the National Cancer Institute (NCI). According to Lin, who is the clinical authorized user for the radioactive administration of the thorium at the NIH Clinical Center, most current forms of systemic radiation therapy using radionuclides emits radiation particles that are very small such as beta particles. But, the higher the mass or energy of the emitted particle, the more tumor damage can be done. Alpha particles, such as Thorium-227, are several thousand times larger than beta particles. Before now, alpha emitters have never been used to treat patients at NIH.

The new drug being tested (BAY 2287411) is made up of two components that are combined into one molecule. First is an antibody that allows the drug to locate and target the mesothelin protein on the cancer cells. Second is the Thorium-227, which is the "active ingredient" of the combined molecule. This is akin to having a smart bomb against cancer cells, where the antibody provides the targeting system, and the Thorium-227 is the radioactive payload. Once bound to tumor cells, the thorium undergoes its natural radioactive decay and exposes tumor cells to lethal doses of alpha radiation.

"Our goal is to demonstrate the safety and tolerability of this drug and to get preliminary evidence of anti-tumor efficacy," said the study's principal investigator, Dr. Raffit Hassan, the Chief of the Thoracic and GI Malignancies Branch and Head or the Thoracic Oncology Section at NCI. "This is a treatment for patients with mesothelioma and ovarian cancer who have failed standard therapies and provides a new treatment approach for treating their cancer."

For more than two decades, Hassan and colleagues have been investigating the protein mesothelin as a target for cancer therapy.

"It feels exciting thanks to the work by Frank and [the NIH Office of Research Services] Division of Radiation Safety. They have been critical in working with the Nuclear Regulatory Commission to allow us to use the Thorium radio-conjugate here. It is a very complicated process, but because of a lot of their work we were able to do it and hopefully this opens the door for Alpha therapies not only for targeting mesothelin but other cancers," Hassan said.

While it may take a number of years to conduct the trial and assess its effectiveness, Hassan said if successful, it could be used on other cancers such as lung cancer and pancreatic cancer.

- Molly Freimuth

All patients, visitors and staff are screened for Covid-19 when they enter the hospital
People working on sewing blankets
Janet Logan
Group of people celebrating Bill Cervenka's 400th platelets donation
Dr. Marta Čeko
The NIH Clinical Center Nutrition Department's new biodegradable cups and plates
NIH Clinical Center staff member
Dr Kadri receives 2018 Science Award
weight, scale and an exercise ball
Dr. Huy Michael
Noah Victoria speaking
Jim Gilman, CC CEO
Dr. Tomislav Mihaljevic, Mihaljevic is Laura Lee, and Dr. James K. Gilman
Dr. Douglas Rosing
Dr. Francis Collins, Dr. Emily Chew and Dr. Jim Gilman
NIH Clinical Center Atrium
Federal Employee Viewpoint Survey - your opinion counts!
David Henderson
A gathering of NIH staff and blood and platelet donors
Dr. James Gilman and Stanley Hess
Lunch and Learn
2019-2020 Introduction to the Principles and Practice of Clinical Research Course now open
mother with a child playing with a toy
Ingrid Harris, Mitzi Kosciulek and Richard Appling pose with two Marines during NIH's 8th Annual Veterans Day Celebration Nov. 12
Dr. Curtis Longlotz speaks at a podium
Tricia Coffey, chief of the Health Information Management department participated as torchbearers
Program graduates pose for a group photo
Rabbi David Shneyer (right) shared songs of healing from the Jewish tradition
NIH Social Media team livestreams the winners on Twitter
Pharmacy symbol icon
NIH Clinical Center releases Strategic Plan
Mary Sparks receiving a flu shot
wristband with ALLERGY on it
Awardees Elise Ferré, Maureen McDonnell, Ruth Parker and Dr. Douglas Rosing
Language Interpreters Program staff
Dr. Harvey Klein
Julianna Nickel playing the flute
CC Research Nursing Department trains University of Guam Nursing students and Faculty
Dr. Francis Collins, Thu Cao and Dr. Jim Gilman
Dr. Jo Shapiro
Jim Howson
Screen capture of Meet Our Doctors, a new feature of the NIH Clinical Center website
Dr. James Gilman, NIH Clinical Center CEO, addresses staff clinicians
Michael Murphy at a podium
Nurses working on a pedigree diagram within a patient's medical record
nurse kneeling beside a pediatric patient
people gathered around computers
Patient standing with care providers
The metabolic kitchen staff creating precisely measured ultra-processed and unprocessed meals for study participants
Attendees of the Open Notes session gathered together